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http://dx.doi.org/10.1016/j.jmu.2013Background: An accurate and convenient technique is needed for assessment of therapeutic
efficacy for ultrasound (US)-guided high-intensity focused ultrasound (HIFU) ablation of uterine
fibroids. The accuracy of contrast-enhanced ultrasonography (CEUS) was tested in this study
using contrast-enhanced magnetic resonance (CEMR) as a standard of reference.
Materials and methods: A total of 67 women with 71 uterine fibroids (mean  standard devi-
ation, 7.6  3.5 cm; range, 4.3e19.0 cm) underwent US-guided HIFU ablation. The immediate
therapeutic efficacy was observed by CEUS performed immediately after treatment. The non-
perfused ablation ratio was measured on CEUS and CEMR. During follow-up, CEUS was
compared with CEMR regarding the detection rate of enlargement of viable fibroids.
Results: Residual viable portions were detected in four patients by CEUS performed just after
US-guided HIFU ablation and which received immediate reablation. There was good agreement
between CEMR and CEUS for the measurement of nonperfused ablation ratio (Intraclass corre-
lation coefficient (ICC)Z 0.912, p < 0.01). During follow-up, CEUS detected all enlargement of
viable fibroid shown on CEMR. The gradual shrinkage of the ablated fibroids was also clearly
depicted by CEUS.ng authors declare no conflicts of interest.
Department of Ultrasound, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China.
o.com.cn (W. Wang).
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CEUS for HIFU Ablation of Uterine Fibroids 23Conclusion: CEUS may be used as a convenient alternative to CEMR in the assessment of ther-
apeutic efficacy for US-guided HIFU ablation of uterine fibroids.
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Open access under CC BY-NC-ND license.Table 1 Patient and uterine fibroid characteristics.
No.
Age (y)
20e30 14
31e40 33
41e50 16Introduction
Uterine fibroids are common benign tumors in the female
genital tract, with an incidence as high as 20e40% in women
of childbearing age [1]. Although most patients remain
asymptomatic, in approximately 25% of women, uterine
fibroids cause symptoms such as menorrhagia, pelvic pain, a
feeling of pelvic fullness, and infertility [2]. Hysterectomy
or myomectomy had been the traditional treatment for
symptomatic uterine fibroids. Because surgical approaches
have a long recovery period, often necessitate general
anesthesia, and are associated with risks of bleeding and
infection, uterus-preserving treatments had become pop-
ular in the past decade [3e13].
High-intensity focused ultrasound (HIFU) ablation is a
promising minimally invasive treatment for symptomatic
uterine fibroids. Under magnetic resonance (MR) or ultra-
sound (US) guidance, coagulation necrosis can be induced in
the focal region inside the fibroids without damaging the
overlying tissue. Studies had proven that HIFU ablation can
yield significant shrinkage of the fibroids and sustained re-
lief of symptoms [7e13].
Accurate imaging assessment is important to evaluate
the therapeutic outcome of HIFU ablation. Contrast-
enhanced magnetic resonance (CEMR) had been the mo-
dality of choice for detecting viable foci and calculating the
nonperfused ablation volume. However, it is relatively
expensive and may not be used in patients with metal im-
plants. It is also inconvenient for US-guided HIFU ablation
because patients must be transferred to the MR unit after
treatment to evaluate the immediate therapeutic
response. In recent years, contrast-enhanced ultrasonog-
raphy (CEUS) has been introduced to assess the therapeutic
efficacy for thermal ablation of liver cancer [14e17], which
can clearly depict the margin of nonenhanced ablation area
and the viable tumor. CEUS showed a high diagnostic ac-
curacy comparable to that of CEMR. Because the results
were encouraging, we aim to evaluate the usefulness of
CEUS in the assessment of therapeutic efficacy for US-
guided HIFU ablation in patients with symptomatic uter-
ine fibroids.> 50 4
Fibroid location
Intramuscular 38
Subserosal 21
Submucosal 8
No. of fibroids
Single 24
Multiple 43
Largest dimension of fibroid
< 10 cm 51
10 cm 16Materials and methods
Patients
From October 2010 to April 2011, 67 premenopausal women
with 71 symptomatic uterine fibroids underwent US-guided
HIFU ablation in our hospital. The patients received CEUS
and CEMR for assessment of therapeutic outcome right
after treatment and during follow-up. The study was
approved by the institutional ethics committee. Writteninformed consent was obtained from all patients at
enrollment.
The age of the patients ranged from 27 years to 53 years
[mean  standard deviation (SD), 35.8  4.5 years]. The
maximum diameter of the largest fibroid in each patient
ranged from 4.3 cm to 19.0 cm (mean  SD, 7.6  3.5 cm).
The patient and fibroid characteristics were summarized in
Table 1. All patients refused surgery because of the minimal
invasiveness of HIFU ablation and the intention to preserve
their uterus.
HIFU ablation procedures
A JC system (Chongqing Haifu Technology, Chongqing,
China) was used for HIFU ablation. The focused US energy is
produced from a therapeutic transducer with a focal length
of 150 mm operating at a frequency of 0.9 MHz. The ther-
apeutic transducer was immersed in a reservoir of degassed
water. In its center, a 3.5e5.0 MHz convex diagnostic US
probe was mounted to provide real-time imaging for
targeting.
During HIFU ablation, the patients were placed in the
prone position, with the abdominal skin in contact with the
degassed water. Treatment was performed under conscious
sedation (fentanyl and midazolam). The fibroids were
divided into sections with 5-mm separation on US. HIFU
exposures were intermittently applied with an acoustic
power of 420e520 W. To avoid thermal damage to adjacent
structures, the focus of the energy beam was kept at least
1 cm away from the border of the fibroids. HIFU exposures
were repeated section by section, in successive sweeps
from the deep to shallow regions until the target area were
ablated.
Fig. 1 Measurement of the size of nonperfused ablation area and ablated fibroids on CEUS and CEMR. The measurement was
performed on the image with the largest lesion size in a comparable plane. (A) The size of the ablated fibroid was measured in
three orthogonal directions on T2-weighted magnetic resonance imaging. The size of the nonperfused ablation area was measured
on CEMR. (B) The size of the ablated fibroid was measured in three orthogonal directions on grayscale ultrasound. The size of the
nonperfused ablation area was measured on CEUS. In this patient, the ablation ratio measured by CEMR was 90.1% and the ablation
ratio measured by CEUS was 90.9%. CEMRZ contrast-enhanced magnetic resonance; CEUSZ contrast-enhanced ultrasonography.
24 Y. Wang et al.
Table 2 Contrast-enhanced ultrasonography and
contrast-enhanced magnetic resonance volume calculation
after ultrasound-guided high-intensity focused ultrasound
ablation of uterine fibroids.
Volume of
nonenhanced
ablation
area (cm3)
Volume of treated
uterine fibroid (cm3)
Ablation
ratio (%)
CEUS 165  109 198  121 83  20
CEMR 159  103 187  116 85  23
CEMR Z contrast-enhanced magnetic resonance;
CEUS Z contrast-enhanced ultrasonography.
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CEUS was performed using a Sequoia 512 US system (Acu-
son, Mountain View, CA, USA) equipped with contrast pulse
sequencing software. The US contrast agent was SonoVue
(Bracco, Milan, Italy). After baseline US scan with a 4V1
transducer (1e4 MHz), a bolus injection of 1.0e2.0 mL
SonoVue was administered via the cubital vein, which was
followed by a 5-mL saline flush. CEUS was performed at a
mechanical index of 0.16e0.18. The target fibroids were
observed continuously for at least 4 minutes.
CEMR was performed using a 1.5 T scanner (Signa Echo-
Speed, GE Healthcare, Milwaukee, WI, USA). The following
sequences were used: a fast spin-echo T1-weighted
sequence with 425/9.2 (repetition time/echo time msec),
a matrix of 256  224, field of view (FOV) of 300 mm, slice
thickness of 5 mm, and slice gap of 1 mm; a fat-suppressed
T2-weighted spin echo sequence with 4000/90, a matrix of
320  224, FOV of 300 mm, slice thickness of 5 mm, and
slice gap of 1 mm; a T1-weighted fast spoiled gradient
recalled echo sequence with fat saturation was used for
contrast scan (125/4.2, a matrix of 320  192, a flip angles
of 12, slice thickness of 5 mm, slice gap of 1 mm, and FOV
of 300 mm). The MR contrast agent was gadopentetate
dimeglumine (Magnevist, Schering, Berlin, Germany), which
was administered as an intravenous bolus of 0.2 mL/kg at
an injection speed of 2 mL/s.
CEUS was performed right after US-guided HIFU abla-
tion. If a significant fraction of the target fibroid still had
blood perfusion, additional HIFU ablation was performed
immediately. CEUS and CEMR were performed on the same
day within 1 week after HIFU ablation to measure the
nonperfused ablation ratio. Then, patients entered the
follow-up protocol, which consisted of CEMR and CEUS at 1-
month, 3-month, and 6-month intervals and every 6 months
thereafter. Areas that did not enhance after contrast
administration were considered to represent necrotic tis-
sue. Enhancing areas were assumed to represent viable
tissue.Fig. 2 A 45-year-old premenopausal woman with a symp-
tomatic fibroid received ultrasound-guided HIFU ablation. Ten
months after treatment, although the patient had no symp-
toms, enlargement of residual viable fibroid was detected on
follow-up CEMR and CEUS. (A) Enlarged viable fibroid (arrows)
shown on CEMR. (B) Enlarged viable fibroid (arrows) shown on
CEUS, similar to that on CEMR. The patient received an addi-
tional HIFU ablation of the residual fibroid. CEMR Z contrast-
enhanced magnetic resonance; CEUS Z contrast-enhanced
ultrasonography; HIFU Z high-intensity focused ultrasound.Measurement of ablation ratio and statistical
analysis
CEUS and CEMR measurement was performed on the image
with the largest lesion size in a comparable plane. The size
of the posttreatment fibroid was measured in three
orthogonal directions on T2-weighted MR and on grayscale
US. The size of the nonperfused ablation area was
measured in three orthogonal directions on CEMR and CEUS
(Fig. 1). The CEUS measurement was made by either of the
two experienced physicians (W.W. and W.Y.). The CEMR
measurement was made by an experienced radiologist
(H.Y.Y.). The volume was simply calculated using the
ellipsoid formula: (D1  D2  D3)  0.523 [18,19]. The
ablation ratio was calculated as the volume of the non-
perfused area divided by the volume of the posttreatment
fibroid. Statistical analysis was performed using Stata
software (version 7.0; Stata Corporation, College Station,
TX, USA). Data were expressed as mean  standard devia-
tion. The agreement between the nonperfused ablation
ratio measured by CEMR and CEUS was analyzed by using
Fig. 3 Shrinkage of ablated fibroids on CEMR and CEUS. (A) For transverse CEMR performed before HIFU ablation (A) and at (B) 1
week, (C) 6 months, and (D) 12 months after US-guided HIFU ablation, the treated fibroid gradually shrank over time. (E) CEUS per-
formed prior to HIFU ablation. For transverse CEUS performed at (F) 1 week (G), 6 months, and (H) 12 months after US-guided HIFU
ablation, the treated fibroid gradually shrank over time. The results of CEUS were similar to that of CEMR. CEMRZ contrast-enhanced
magnetic resonance; CEUSZ contrast-enhanced ultrasonography; HIFUZ high-intensity focused ultrasound; USZ ultrasound.
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considered statistically significant.
Results
HIFU ablation was successfully performed in all patients
without major complications. A well-defined nonperfused
ablation areawas observed in all patients onCEUSperformed
immediately after HIFU ablation. Of these, large viable
fractions were found in five patients, and additional HIFU
ablation was performed immediately to ensure therapeutic
efficacy. After US-guided HIFU ablation, the volume of the
fibroid and the ablation area was 187  116 cm3 (range,
28e1670 cm3) and 159  103 cm3 (range, 26e1204 cm3) on
CEMR, respectively, and 198 121 cm3 (range, 30e1750 cm3)
and 165  109 cm3 (range, 28e1256 cm3) on CEUS, respec-
tively. The nonperfused ablation ratio was 85 23% on CEMR
and 83 20%onCEUS, respectively (Table 2). Therewas good
agreement between CEMR and CEUS for measurement of
nonperfused ablation ratio (Intraclass correlation coefficient
(ICC)Z 0.910, p < 0.01).
During follow-up, enlargement of residual fibroid was
observed in four patients on both CEMR and CEUS (Fig. 2),
which was treated by additional US-guided HIFU ablation.
The treated fibroids shrank significantly over time on both
CEMR and CEUS (Fig. 3).
Discussion
Prompt and accurate imaging evaluation of the percentage
of coagulation necrosis is important for HIFU ablation of
symptomatic fibroids. Previous studies have shown that a
higher nonperfused ablation ratio correlates with marked
reduction in symptom severity and a significant decrease in
the number of patients undergoing other fibroid treatments
after HIFU ablation [9,10]. A higher nonperfused ablation
ratio was associated with greater fibroid shrinkage and
improved relief of symptoms [11].
Unlike Western countries where MR-guided HIFU ablation
is popular, US-guided HIFU ablation is the mainstay of HIFU
ablation in China. Real-time US is a convenient imaging
technique for guidance of HIFU ablation; however, it is a
poor choice for assessing treatment efficacy. An increase in
echogenicity after US-guided HIFU ablation may provide a
rough estimation of the ablated area, but it is not reliable
enough to identify boundaries of the ablated areas. Pa-
tients who completed US-guided HIFU ablation must be
transferred to the MR unit and undergo CEMR for accurate
assessment of the immediate therapeutic response. With
the advent of second-generation US contrast agent such as
SonoVue and dedicated software, CEUS can sensitively de-
pict tissue vascularity in real time, making it appropriate
for evaluation of treatment efficacy during and after local
ablation therapy [14e17]. In this study, CEUS performed
immediately after treatment proved to be particularly
valuable for US-guided HIFU ablation, because viable frac-
tions of the ablated fibroids could be identified and reab-
lated immediately to ensure therapeutic outcome.
Statistical analyses suggested that there was good agree-
ment between CEMR and CEUS for the measurement of
nonperfused ablation ratio. Therefore, CEUS could be usedas a reliable method for assessing the outcome of US-guided
HIFU ablation. During follow-up, CEUS proved sensitive for
detecting the enlargement of residual viable fibroids
because all enlarged viable portions were screened out by
CEUS. It also clearly depicted the gradual shrinkage of
treated fibroids. Because CEUS was sensitive and accurate
and can be performed at the patient’s bedside, we believe
it could be a convenient and reliable method to assess the
therapeutic efficacy of US-guided HIFU ablation of fibroid.
In this study, CEUS also exhibited some limitations. First,
CEUS is not a standardized imaging technique but CEMR is, and
accurate assessment by CEUS requires the expertise of the
observer. Second, only one fibroid could be continuously
observed during CEUS. Patients with multiple fibroids require
several contrast injections to observe all ablated fibroids.
Third, thehyperechoic vapors generatedbyHIFUablationmay
hamper accuratemeasurement of the fibroid size on grayscale
US, and accurate CEUS assessment should be done after the
disappearance of the hyperechoic vapors. Fourth, there are
differentmorphological types of uterinefibroids, ranging from
uniloculated tumors to disseminated small myomatous nod-
ules gathering together to form a large tumor. Moreover, some
fibroids, especially larger ones, are composed of degenerated
components. Additional studies are warranted to explore if
these factors interfere with the estimation of blood perfusion
of fibroids using CEMR and CEUS.
In conclusion, our study showed that CEUS could be used
as a convenient alternative to CEMR in the assessment of
therapeutic efficacy for US-guided HIFU ablation of uterine
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